Gangliosides: Glycosphingolipids essential for normal neural development and function

Trends in Biochemical Sciences

Volumn 40, Issue 7, 2015, Pages 397-406

  Schengrund, Cara Lynne ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Dementia; Gangliosides; Lipid rafts; Neural development; Signal transduction

Indexed keywords

GANGLIOSIDE; GLYCOSPHINGOLIPID;

AGING; ALZHEIMER DISEASE; BIOCHEMICAL COMPOSITION; BRAIN DEVELOPMENT; BRAIN FUNCTION; CELL FUNCTION; CELL MATURATION; CYTOLOGY; DEMENTIA; GLYCOCALYX; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; LIFESPAN; LIPID RAFT; NERVE CELL DIFFERENTIATION; NERVE FUNCTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CARBOHYDRATE ANALYSIS; CELL DIFFERENTIATION; CELL MEMBRANE; CONFORMATION; DEGENERATIVE DISEASE; EMBRYOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CELL DIFFERENTIATION; GANGLIOSIDES; GLYCOCALYX; HUMANS; MEMBRANE MICRODOMAINS; MOLECULAR SEQUENCE DATA; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84930819900     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.03.007     Document Type: Review

References (115)

1. Benett H.S. Morphological aspects of extracellular polysaccharides J. Histochem. Cytochem. 1963, 11:14-23.
2. Gabius H-J., et al. From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem. Sci. 2011, 36:298-313.
3. Pedersen M.E., et al. An epidermal microRNA regulates neuronal migration through control of the cellular glycosylation state. Science 2013, 341:1404-1408.
4. Corfield A., Berry M. Current aspects of eukaryotic glycosylation. Trends Biochem. Sci. 2015, 40:351-359.
5. Rapport M.M. Introduction to the biochemistry of gangliosides. Gangliosides in neurological and neuromuscular function, development, and repair 1981, xv-xix. Raven Press. M.M. Rapport, A. Gorio (Eds.).
6. Thudichum J.L.W. A Treatise on the Chemical Constitution of Brain 1884, Bailliere, Tindall, and Cox.
7. Fu B.M., Tarbell J.M. Mechano-sensing and transduction by endothelial surface glycocalyx: composition, structure, and function. Wiley Interdiscip. Rev. Syst. Biol. Med. 2013, 5:381-390.
8. Aureli M., et al. Gangliosides and cell surface ganglioside glycohydrolases in the nervous system. Adv. Neurobiol. 2014, 9:223-244.
9. Schengrund C-L., Garrigan O.W. A comparative study of gangliosides from brains of various species. Lipids 1969, 4:488-495.
10. Colsch B., et al. Molecular microscopy of brain gangliosides: illustrating their distribution in hippocampal cell layers. ACS Chem. Neurosci. 2011, 2:213-222.
11. Ohmi Y., et al. Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem. Res. 2012, 37:1185-1191.
12. Hering H., et al. Lipid rafts in maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 2003, 23:3262-3271.
13. Kiarash A., et al. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 1994, 269:11138-11146.
14. Bremer E.G., et al. Ganglioside-mediated modulation of cell growth, growth factor binding, and receptor phosphorylation. J. Biol. Chem. 1984, 259:6818-6825.
15. Simpson M.A., et al. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 2004, 36:1225-1229.
16. Yamashita T., et al. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2725-2730.
17. Husain S., et al. Variants of ST8SIA1 are associated with risk of developing multiple sclerosis. PLoS ONE 2008, 3:e2653.
18. Xu Y-H., et al. Multi-system disorders of glycosphingolipid and ganglioside metabolism. J. Lipid Res. 2010, 51:1643-1675.
19. Cui H., et al. Proteoglycans in the central nervous system: role in development, neural repair, and Alzheimer's disease. IUBMB Life 2013, 65:108-120.
20. Yu R.K., et al. The role of glycosphingolipid metabolism in the developing brain. J. Lipid Res. 2012, 50:S440-S445.
21. Svennerholm L. Chromatographic separation of human brain gangliosides. J. Neurochem. 1963, 10:613-623.
22. Yanagisawa M. Stem cell glycolipids. Neurochem. Res. 2011, 36:1623-1635.
23. Yoshikawa M., et al. Mice lacking ganglioside GM3 synthase exhibit complete hearing loss due to selective degeneration of the organ of Corti. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9483-9488.
24. Niimi K., et al. Impairment of neuropsychological behaviors in ganglioside GM3-knockout mice. Biochem. Biophys. Res. Commun. 2011, 406:524-528.
25. Mitchell M.D., et al. Transfer of gangliosides across the human placenta. Placenta 2012, 33:312-316.
26. Gustavsson M., et al. Maternal supplementation with a complex milk lipid mixture during pregnancy and lactation alters neonatal brain lipid composition but lacks effect on cognitive function in rats. Nutr. Res. 2010, 30:279-289.
27. Vickers M.H., et al. Supplementation with a mixture of complex lipids derived from milk to growing rats results in improvements in parameters related to growth and cognition. Nutr. Res. 2009, 29:426-435.
28. Yamamoto N., et al. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim. Biophys. Acta 2008, 1778:2717-2726.
29. Lingwood D., et al. Cholesterol modulates glycolipid conformation and receptor activity. Nat. Chem. Biol. 2011, 7:260-262.
30. Fantini J., et al. Cholesterol accelerates the binding of Alzheimer's β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. Front. Physiol. 2013, 4:120.
31. Posse de Chaves E., Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 2010, 584:1746-1750.
32. Valdes-Gonzalez T., et al. New approach for glycol- and lipidomics- Molecular scanning of human brain gangliosides by TLC-blot and MALDI-QIT-TOF MS. J. Neurochem. 2011, 116:678-683.
33. Ledeen R.W., Wu G. The multi-tasked life of ganglioside GM1, a true factotum of nature. Trends Biochem. Sci. 2015, 40:407-418.
34. Miyakoshi L.M., et al. Role of the 9-O-acetyl GD3 in subventricular zone neuroblast migration. Mol. Cell Neurosci. 2012, 49:240-249.
35. Yu R.K., et al. Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect. Immun. 2006, 74:6517-6527.
36. Yao D., et al. Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice. J. Neurosci. 2014, 34:880-891.
37. Chung E.S., et al. GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons. BMC Neurosci. 2010, 11:74.
38. Ando S. Neuronal dysfunction with aging and its amelioration. Proc. Jpn. Acad. Ser. B: Phys. Biol. Sci. 2012, 88:266-282.
39. Ledeen R.W., et al. Beyond glycoproteins as galectin counterreceptors: tumor-effector T cell growth control via ganglioside GM1. Ann. N.Y. Acad. Sci. 2012, 1253:206-221.
40. Sakaguchi M., et al. Impaired spatial and contextual memory formation in galectin-1 deficient mice. Mol. Brain 2011, 4:33.
41. Han H., et al. Synergistic effects of galectin-1 and reactive astrocytes on functional recovery after contusive spinal cord injury. Arch. Orthop. Trauma Surg. 2011, 131:829-839.
42. Kopitz J., et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 2001, 276:35917-35923.
43. Linnartz-Gerlach B., et al. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins. Neurosci. 2014, 275:113-124.
44. Kappagantula S., et al. Neu3 sialidase-mediated ganglioside conversion is necessary for axon regeneration and is blocked in CNS axons. J. Neurosci. 2014, 34:2477-2492.
45. Schnaar R.L., et al. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol. Rev. 2014, 94:461-518.
46. Salminen A., Kaamiranta K. Siglec receptors and hiding plaques in Alzheimer's disease. J. Mol. Med. 2009, 87:697-701.
47. Gabius H-J. The magic of the sugar code. Trends Biochem. Sci. 2015, 40:341.
48. Gabius H-J., et al. The glycobiology of the CD system: a dictionary for translating marker designations into glycan/lectin structure and function. Trends Biochem. Sci. 2015, 40:360-376.
49. Gout E., et al. Carbohydrate recognition properties of human ficolins Glycan array screening reveals the sialic acid binding specificity of M-ficolin. J. Biol. Chem. 2010, 285:6612-6622.
50. Schengrund C.L. Roles of carbohydrates in the interaction of pathogens with neural cells. Adv. Neurobiol. 2014, 9:395-413.
51. Lee R.T., Lee Y.C. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj. J. 2000, 17:543-551.
52. Hebert L.E., et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013, 80:1778-1783.
53. Hardy D., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the way to therapeutics. Science 2002, 277:35113-35117.
54. Alonso A., et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6923-6928.
55. Stittmatter A.M., et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:1977-1981.
56. Polvikoski T., et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. New Eng. J. Med. 1995, 333:1242-1247.
57. Yamamoto N., et al. Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J. Neurochem. 2012, 121:619-628.
58. Yamamoto N., et al. Leptin inhibits amyloid β-protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway. J. Neurochem. 2014, 131:323-332.
59. Ali-Rahmani F., et al. Effect of HFE variants on sphingolipid expression by SH-SY5Y human neuroblastoma cells. Neurochem. Res. 2011, 36:1687-1696.
60. Combarros O., et al. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2003, 15:151-154.
61. Percy M., et al. Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-supplemented Ontario population. J. Alzheimers Dis. 2008, 14:69-84.
62. Ali-Rahmani F., et al. H63D mutation in HFE alters cholesterol metabolism and induces memory impairment. Neurobiol. Aging 2013, 35. 1511.e1-12.
63. Correia A.P., et al. CAT53 and HFE alleles in Alzheimer's disease: a putative protective role of the C282Y HFE mutation. Neurosci. Lett. 2009, 457:129-132.
64. Waheed A., et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:12384-12389.
65. Novak A., et al. Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies. Glycobiology 2013, 23:1230-1239.
66. Piehler A.P., et al. A-subclass ATP-binding cassette proteins in brain lipid homeostasis and neurodegeneration. Front. Psychiatry 2012, 3:17.
67. Taki T. An approach to glycobiology from glycolipidomics: ganglioside molecular scanning in the brains of patients with Alzheimer's disease by TLC-blot/matrix assisted laser desorption/ionization-time of flight MS. Biol. Pharm. Bull. 2012, 35:1642-1647.
68. Pernber Z., et al. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2012, 33:174-188.
69. Mutoh T., et al. Abnormal cross-talk between mutant presenilin 1 (I143T G384A) and glycosphingolipid biosynthesis. FASEB J. 2012, 26:3065-3074.
70. Chapman J., et al. Antibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci. Lett. 1988, 86:235-240.
71. Ariga T., et al. Anti-Chol-1 antigen, GQ1bα, antibodies are associated with Alzheimer's disease. PLoS ONE 2013, 8:e0063326.
72. Miura Y., et al. Autoantibodies to GM1 and GQ1ba are not biological markers of Alzheimer's disease. J. Alzheimers Dis. 2014, 42:1165-1169.
73. Kubo S., et al. Lipid rafts involvement in the pathogenesis of Parkinson's disease. Front. Biosci. 2015, 20:263-279.
74. Schneider J.S., et al. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992, 256:843-846.
75. Martinez Z., et al. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007, 46:1868-1877.
76. Di Pasquale E., et al. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of α-synuclein is corrected by GM3 but not by GM1 gangliosides. J. Mol. Biol. 2010, 397:202-218.
77. Wu G., et al. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J. Neurosci. Res. 2012, 90:1997-2008.
78. Schneider J.S., et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 2013, 324:140-148.
79. Desplats P.A., et al. Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol. Dis. 2007, 27:265-277.
80. Maglione V., et al. Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1. J. Neurosci. 2010, 30:4072-4080.
81. Ariga T. Pathogenic role of ganglioside metabolism in neurodegenerative diseases. J. Neurosci. Res. 2014, 92:1227-1242.
82. Gong J-S., et al. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J. Biol. Chem. 2002, 277:29919-29926.
83. Valenza M., Cattanaeo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
84. Abad-Rodríguez J., Díez-Revuelta N. Axon glycoprotein routing in nerve polarity, function and repair. Trends Biochem. Sci. 2015, 40:385-396.
85. Okajima T., et al. Molecular cloning and expression of mouse GD1α/GT1aα/GQ1bα synthase (ST6GalNAc VI) gene. J. Biol. Chem. 2000, 275:6717-6723.
86. Merrill A.H. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 2011, 111:6387-6422.
87. Maccioni H.J., et al. Cellular and molecular biology of glycosphingolipid glycosylation. J. Neurochem. 2011, 117:589-602.
88. Chisada S-I., et al. Zebrafish and mouse alpha2,3-sialyltransferases responsible for synthesizing GM4 ganglioside. J. Biol. Chem. 2009, 284:30534-30546.
89. Sturgill E.R., et al. Biosynthesis of the major brain gangliosides GD1a and GT1b. Glycobiology 2012, 22:1289-1301.
90. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
91. Kraft M.L. Plasma membrane organization and function: moving past lipid rafts. Mol. Biol. Cell 2013, 24:2765-2768.
92. Gao X., Zhang J. Akt signaling dynamics in plasma membrane microdomains visualized by FRET-based reporters. Commun. Integr. Biol. 2009, 2:32-34.
93. Chang J.C., Rosenthal S.J. Visualization of lipid raft membrane compartmentalization in living RN46A neuronal cells using single quantum dot tracking. ACS Chem. Neurosci. 2012, 3:737-743.
94. Makino A., et al. Visualization of the heterogeneous membrane distribution of sphingomyelin associated with cytokinesis, cell polarity, and sphingolipidosis. FASEB J. 2015, 29:477-493.
95. Rosa Borges A., et al. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology 2010, 408:80-88.
96. Ohmi Y., et al. Gangliosides play pivotal roles in the regulation of complement systems and in the maintenance of integrity in nerve tissues. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22405-22410.
97. Haarlalka G.V., et al. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain 2013, 136:3618-3624.
98. Zhang J.Z., et al. Monosialotetrahexosy-1 ganglioside attenuates diabetes-enhanced brain damage after transient forebrain ischemia and suppresses phosphorylation of ERK1/2 in the rat brain. Brain Res. 2010, 1344:200-208.
99. Ledeen R.W., et al. Nuclear sphingolipids: metabolism and signaling. J. Lipid Res. 2008, 49:1176-1186.
100. Wu G., et al. Induction of calcium influx through TRPC5 channels by cross-linking of GM1 ganglioside-associated with α5β1 integrin initiates neurite outgrowth. J. Neurosci. 2007, 27:7447-7458.
101. Newburn E.N., et al. GM1 ganglioside enhances Ret signaling in striatum. J. Neurochem. 2014, 130:541-554.
102. Botto L., et al. Role of lipid rafts and GM1 in the segregation and processing of prion protein. PLoS ONE 2014, 9:e98344.
103. Ichikawa N., et al. Binding of laminin-1 to monosialoganglioside GM1 in lipid rafts is crucial for neurite outgrowth. J. Cell Sci. 2009, 122:289-299.
104. Sorice M. Ganglioside GD3 as a raft component in cell death regulation. Anticancer Agents Med. Chem. 2012, 12:376-382.
105. Yuyama K., et al. Ganglioside GD3 monoclonal antibody-induced paxillin tyrosine phosphorylation and filamentous actin assembly in cerebellar growth cones. J. Neurochem. 2011, 116:845-850.
106. Wang J., Yu R.K. Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:19137-19142.
107. Kanatsu Y., et al. Gangliosides stimulate bradykinin B2 receptors to promote calmodulin kinase II-mediated neuronal differentiation. J. Biochem. 2012, 152:63-72.
108. Zhang G., et al. Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth. J. Neurosci. 2011, 31:1664-1675.
109. Ando S., et al. Synaptic function of cholinergic-specific Chol-1α ganglioside. Neurochem. Res. 2004, 29:857-867.
110. Watanabe S., et al. Involvement of ganglioside GT1b in glutamate release from neuroblastoma cells. Neurosci. Lett. 2012, 517:140-143.
111. Shin M.K., et al. The ganglioside GQ1b regulates BDNF expression via the NMDA receptor signaling pathway. Neuropharmacology 2014, 77:414-421.
112. Jiang L., et al. Effects of gangliosides on the activity of the plasma membrane Ca2+-ATPase. Biochim. Biophys. Acta 2014, 1838:1255-1265.
113. Miyagi T., et al. Plasma membrane-associated sialidase as a crucial regulator of transmembrane signalling. J. Biochem. 2008, 144:279-285.
114. Bonardi D., et al. Sialidase NEU3 dynamically associates to different membrane domains specifically modifying their ganglioside pattern and triggering Akt phosphorylation. PLoS ONE 2014, 9:e99405.
115. Schengrund C-L. Lipid rafts: keys to neurodegeneration. Brain Res. Bull. 2010, 82:7-17.